NCT02338349 2022-08-18A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerStemline Therapeutics, Inc.Phase 1 Completed57 enrolled